"My interests are focused on the use of monoclonal antibodies that bind to the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors for cancer therapy in combination with chemotherapy agents and radiation. The research involves investigation of the mechanisms of enhanced cytotoxicity produced by combination treatment with TRAIL death receptor antibodies and chemoradiation. Orthotopic and metastatic breast and pancreatic cancer xenograft models are being used to optimize therapeutic regimens."
Sally B. Lagan
Phone (205) 934-6292
Shelby Biomedical Research Building
1825 University Ave South
Birmingham, AL 35294-2182
|Education and Postdoctoral Training:
- B.S. Carnegie Institute of Technology, Pittsburgh, PA 1967, Physics
- M.S. University of Rochester, Rochester, NY 1970, Radiation Biophysics
- Ph.D. University of Rochester, Rochester, NY 1972, Biophysics-Immunology
- Research Associate, University of Minnesota, 1972-1974
Please click on "Publications" to view a full listing.
|Awards / Honors:
- Elected a member of Sigma Xi, 1971
- AEC Research Trainee and NIH Trainee in Biophysics, Department of Radiation Biology and Biophysics, University of Rochester, 1969-1972
- Radiology Centennial, Inc., Award of Honor, 1995
- Elected a member, Board of Directors, Radiopharmaceutical Science Council, Society of Nuclear Medicine, 1998
- Avon Foundation Investigator, 2000-2003
- John R. Durant Award for Excellence in Cancer Research, UAB Comprehensive Cancer Center Distinguished Faculty Award, 2002.
- John Hanephin Award of Research Excellence, John Hanephin Pancreatic Cancer Research Support Fund, 2005.